These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Protection of pancreatic beta-cells: is it feasible? Bonora E Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375 [TBL] [Abstract][Full Text] [Related]
6. Antidiabetogenic efficiency of menthol, improves glucose homeostasis and attenuates pancreatic β-cell apoptosis in streptozotocin-nicotinamide induced experimental rats through ameliorating glucose metabolic enzymes. Muruganathan U; Srinivasan S; Vinothkumar V Biomed Pharmacother; 2017 Aug; 92():229-239. PubMed ID: 28549291 [TBL] [Abstract][Full Text] [Related]
7. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832 [TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress. Shyr ZA; Yan Z; Ustione A; Egan EM; Remedi MS PLoS One; 2022; 17(2):e0258054. PubMed ID: 35180212 [TBL] [Abstract][Full Text] [Related]
10. Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activation. Doliba NM; Fenner D; Zelent B; Bass J; Sarabu R; Matschinsky FM Diabetes Obes Metab; 2012 Oct; 14 Suppl 3(0 3):109-19. PubMed ID: 22928571 [TBL] [Abstract][Full Text] [Related]
11. Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure. Kluth O; Mirhashemi F; Scherneck S; Kaiser D; Kluge R; Neschen S; Joost HG; Schürmann A Diabetologia; 2011 Mar; 54(3):605-16. PubMed ID: 21107520 [TBL] [Abstract][Full Text] [Related]
12. Is Type 2 Diabetes a Glycogen Storage Disease of Pancreatic β Cells? Ashcroft FM; Rohm M; Clark A; Brereton MF Cell Metab; 2017 Jul; 26(1):17-23. PubMed ID: 28683284 [TBL] [Abstract][Full Text] [Related]
13. Delayed onset of hyperglycaemia in a mouse model with impaired glucagon secretion demonstrates that dysregulated glucagon secretion promotes hyperglycaemia and type 2 diabetes. Gustavsson N; Seah T; Lao Y; Radda GK; Südhof TC; Han W Diabetologia; 2011 Feb; 54(2):415-22. PubMed ID: 20978738 [TBL] [Abstract][Full Text] [Related]
14. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179 [TBL] [Abstract][Full Text] [Related]
15. Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes. Kim MJ; Kim MN; Min SH; Ham DS; Kim JW; Yoon KH; Park KS; Jung HS Metabolism; 2019 Aug; 97():87-91. PubMed ID: 30615948 [TBL] [Abstract][Full Text] [Related]
16. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection. Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658 [TBL] [Abstract][Full Text] [Related]
17. Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes. Asghar Z; Yau D; Chan F; Leroith D; Chan CB; Wheeler MB Diabetologia; 2006 Jan; 49(1):90-9. PubMed ID: 16362284 [TBL] [Abstract][Full Text] [Related]
18. Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro. Wu GZ; Hong G; Zhang WP; Zhang HB Arzneimittelforschung; 2009; 59(11):550-6. PubMed ID: 20066963 [TBL] [Abstract][Full Text] [Related]
19. Hyperglycaemia compensates for the defects in insulin-mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with type 2 (non-insulin-dependent) diabetes mellitus. Vaag A; Damsbo P; Hother-Nielsen O; Beck-Nielsen H Diabetologia; 1992 Jan; 35(1):80-8. PubMed ID: 1541385 [TBL] [Abstract][Full Text] [Related]
20. Protective effects of Ficus carica leaves on glucose and lipids levels, carbohydrate metabolism enzymes and β-cells in type 2 diabetic rats. Stephen Irudayaraj S; Christudas S; Antony S; Duraipandiyan V; Naif Abdullah AD; Ignacimuthu S Pharm Biol; 2017 Dec; 55(1):1074-1081. PubMed ID: 28193094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]